Engineered immune cells join forces with checkpoint drugs to fight hard-to-treat sarcomas
NCT ID NCT04995003
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This early-phase study tests whether giving specially engineered immune cells (HER2-CAR T cells) together with an immune checkpoint inhibitor (pembrolizumab or nivolumab) is safe and can help people with advanced sarcoma. About 25 participants will receive chemotherapy to prepare their bodies, then the CAR T cells, followed by the checkpoint drug. Researchers will also study stool bacteria to see if they affect treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.